2 / 18
Page 56
Notes:
conferenceseries
.com
Volume 2, Issue 4 (Suppl)
Breast Can Curr Res, an open access journal
Breast Pathology 2017
August 23-24, 2017
August 23-24, 2017 Toronto, Canada
4
th
World Congress on
Breast Pathology and Cancer Diagnosis
Novel hyper methylated miRNA genes and its potential targets in breast cancer
Eleonora A Braga
Institute of General Pathology and Pathophysiology, Russia
E
pigenetic mechanisms including DNA methylation and interaction between miRNAs and mRNAs are the most dynamic
mechanisms of genes deregulation in cancer. The aim of the study was to identify novel miRNA genes, regulated by DNA
methylation, and target genes involved in the apoptosis, in breast cancer (BC). We used 58 paired (tumor/normal) BC samples,
methylation-specific PCR, and quantitative PCR. Algorithms
of miR
Walk 2.0 database and the IBM SPSS statistics base 20
software package were used. We observed hyper methylation of 9 miRNA genes, and for the first time –
of MIR
-
127, -132,
-1258
and -
193a
, and hypo-methylation
of MIR-191
. Using qPCR, we established a strong correlation between promoter
methylation and expression levels for 10 miRNA genes, demonstrating the functional importance of altered methylation
patterns. A strong association between hyper methylation
of MIR
-127 and
MIR-125b-1
and BC progression, particularly metastasis
was found.The negative correlations were revealed between expression level alterations of 3 genes and 6 potential regulatorymiRNAs
for the following pairs:
BCL2
–miR-124-3p, -212-3p, -24.2-5p;
DAPK1
–
miR-127
-5p, miR-9;
RASSF1 (A)
–miR-375 (Rs=-0.43 - -0.32,
p≤0.01, p≤0.05). The results of transfection of MCF7 cell line with miR-124-3p duplex oligonucleotide analogues strengthened the
hypothesis on the direct or indirect interaction of this miRNAwithmRNA of the
BCL2
gene. Thus, novel hyper methylated miRNA
genes and potential interactions of
DAPK1
,
BCL2
, and
RASSF1 (A)
mRNAs with a number
of miR
NAs were identified that
could be useful as markers and potential targets in combined BC therapy.
Biography
Eleonora A Braga has completed her PhD at Lomonosov Moscow State University, Bioorganic Chemistry Department. She has taken part in Russian Human
Genome Project and HUGO. She was an Invited Principle Investigator at Karolinska Institute (Stockholm, Sweden, 1999-2000). She has completed her full
Dr. of Biology Sc. at Engelhardt Institute of Molecular Biology in 2007. She is a head of Laboratory of Pathogenomics and Transcriptomics at Institute of
General Pathology and Pathophysiology, Moscow, Russia. She has published more than 70 papers in reputed Journals.
eleonora10_45@mail.ruEleonora A Braga, Breast Can Curr Res 2017, 2:4 (Suppl)
DOI: 10.4172/2572-4118-C1-009